ArticleFrontiers in oncology2025
Study on the regulation mechanism of TBX5 gene and Gegen Qinlian decoction on colorectal cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating network pharmacology, molecular docking, and experimental verification to investigate the mechanism of baicalein in colorectal cancer.Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: TBX5 is a key protein regulated by the TGF-β/Smad3 pathway, which plays a significant role in colorectal cancer (CRC) development. This study aims to investigate the interplay between Gegen Qinlian Decoction (GQD), TBX5, and CRC mechanisms. Methods: The Cancer Genome Atlas (TCGA-CRC) dataset from the TCGA database was utilized for the study. Differential expression analysis was conducted to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs). Subsequently, analyses were performed focusing on TBX5, encompassing pan-cancer evaluation, protein-level expression assessment, and enrichment analysis. Correlation analyses were carried out to investigate the relationships between TBX5, clinical characteristics, prognosis, and key pathways in CRC. Furthermore, immune analysis, network construction, drug prediction, and molecular docking studies were conducted. Results: A total of 1,834 differentially expressed genes (DEGs) were identified in TCGA-CRC. TBX5 exhibited elevated expression levels in CRC compared to other cancer types and normal tissues, correlating with lower survival rates in the high TBX5 expression cohort. Additionally, SPTBN4, RP11-35N6.1, CHD5, SLC4A8, KLHL32, MAP2, and ATP8A2 were found to be prognostic markers for patient outcomes. Age, N, and M stages were identified as significant independent prognostic factors for CRC. Notably, there was a significant upregulation of cell stemness, epithelial-mesenchymal transition (EMT), and angiogenesis-related genes in the high TBX5 expression group. Furthermore, the prognostic significance of 10 immune cell types, including mast cells, myeloid-derived suppressor cells (MDSCs), and monocytes, was evident. Thirteen key miRNAs were identified, and an mRNA-miRNA-lncRNA regulatory network was constructed, revealing relationships such as TBX5-hsa-mir-1270-TMPO-AS1. Molecular docking analyses demonstrated favorable binding of active compounds like formononetin and cinnamic acid to TBX5. Conclusion: Our findings suggested a potential association between GQD, TBX5-related genes, and CRC progression, which could provide valuable insights for the diagnosis and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.